RecruitingNot ApplicableNCT03560583

Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial


Sponsor

Barzilai Medical Center

Enrollment

60 participants

Start Date

May 5, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients. Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum. The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 54 Years

Inclusion Criteria1

  • Poor response according to "Bologna criteria"

Exclusion Criteria3

  • Allergy to metoclopramide
  • Prolactinemia
  • Women treated with dopamine agonists

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetoclopramide

Metoclopramide 10 mg BID

DRUGPlacebo Oral Tablet

Placebo 10 mg BID


Locations(1)

Barzilai University Medical Center

Ashkelon, Ashkelon District, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03560583